Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 135
Filter
1.
Adv Food Nutr Res ; 109: 43-66, 2024.
Article in English | MEDLINE | ID: mdl-38777417

ABSTRACT

Historically vitamin D deficiency had devastating consequences for children causing rickets resulting in severe bone deformities often leading to death. The mystery of the cause of rickets finally came to light when it was observed that cod liver oil and sunlight could prevent and cure rickets. The first vitamin D to be discovered was vitamin D2 from ergosterol in ultraviolet irradiated yeast. Vitamin D3 was discovered from UV exposure to the skin. Investigations revealed the two major functions of vitamin D were to increase intestinal calcium and phosphate absorption and mobilize calcium from the skeleton to maintain calcium and phosphorus homeostasis. Later studies demonstrated that vitamin D does not have an active role in bone mineralization. Vitamin D deficiency results in secondary hyperparathyroidism increasing bone resorption. As a result, this decreases bone mineral content and compromises the architectural integrity increasing risk for fracture. Vitamin D deficiency has also been shown to enhance aging of the bone causing cracks and enhancing bone fractures. Vitamin D deficiency also causes osteomalacia. Therefore, vitamin D sufficiency is extremely important to maximize bone health throughout life. It helps to prevent bone loss, but it cannot restore bone loss due to increased bone resorption that can occur under a variety of circumstances including menopause. The Endocrine Society Guidelines recommends for all ages that adequate vitamin D obtained from the sun, foods and supplements is necessary in order to maintain a circulating concentration of 25-hydroxyvitamin D of at least 30 ng/mL for maximum bone health.


Subject(s)
Vitamin D Deficiency , Vitamin D , Humans , Vitamin D Deficiency/complications , Bone and Bones/metabolism , Rickets/prevention & control , Rickets/etiology , Bone Density/drug effects , Osteomalacia/prevention & control , Dietary Supplements
2.
N Z Med J ; 134(1541): 86-95, 2021 09 03.
Article in English | MEDLINE | ID: mdl-34531599

ABSTRACT

BACKGROUND: Severe prolonged vitamin D deficiency can cause rickets or osteomalacia. Both can be prevented by sunshine exposure or vitamin D supplementation. Although New Zealand guidance does not recommend vitamin D supplementation for the general population, it can be considered for individuals at risk of vitamin D deficiency. Routine measurement of 25-hydroxyvitamin D (25OHD) is also considered unnecessary. METHODS: We investigated the rates of vitamin D supplementation, rickets and osteomalacia in New Zealand, and of 25OHD results in Auckland, over the last two decades. RESULTS: Vitamin D prescriptions increased 14-fold, from 86,295/year to 1,215,507/year, between 2003 and 2019, with medication costs alone in 2019 being >$1 million. Despite these changes, the annual prevalence of hospital admissions for rickets, osteomalacia and unspecified vitamin D deficiency remained low and stable (10-20/year). 25OHD concentrations increased between 2002 and 2003 and between 2009 and 2019, and in the later time-period, 25OHD tests mainly identified individuals without vitamin D deficiency (40-50% >75nmol/L, 65-70% >50nmol/L and only 7-12.5% <25nmol/L). CONCLUSIONS: Osteomalacia and rickets persist at low rates despite widespread, increasingly costly vitamin D supplementation and testing, which largely identifies individuals without vitamin D deficiency. These results suggest that vitamin D guidance and practice in New Zealand should change.


Subject(s)
Cholecalciferol/therapeutic use , Osteomalacia/drug therapy , Rickets/drug therapy , Vitamin D Deficiency/drug therapy , Vitamins/therapeutic use , Blood Chemical Analysis , Dietary Supplements , Humans , New Zealand/epidemiology , Osteomalacia/epidemiology , Osteomalacia/prevention & control , Practice Guidelines as Topic , Practice Patterns, Physicians'/statistics & numerical data , Prevalence , Rickets/epidemiology , Rickets/prevention & control , Risk Assessment , Vitamin D/analogs & derivatives , Vitamin D/blood , Vitamin D Deficiency/diagnosis , Vitamin D Deficiency/epidemiology , Vitamin D Deficiency/prevention & control
3.
J Nutr Sci ; 9: e47, 2020.
Article in English | MEDLINE | ID: mdl-33101664

ABSTRACT

The study aimed to estimate vitamin D intake and plasma/serum 25-hydroxyvitamin D (25(OH)D) concentrations, investigate determinants of 25(OH)D concentrations and compare two 25(OH)D assays. We conducted two nationwide cross-sectional studies in Sweden with 206 school children aged 10-12 years and 1797 adults aged 18-80 years (n 268 provided blood samples). A web-based dietary record was used to assess dietary intake. Plasma/serum 25(OH)D was analysed by liquid chromatography-mass spectrometry (LC-MS) and immunoassay in adults and LC-MS/MS in children. Most participants reported a vitamin D intake below the average requirement (AR), 16 % of children and 33 % of adults met the AR (7⋅5 µg). In adults, plasma 25(OH)D below 30 and 50 nmol/l were found in 1 and 18 % of participants during the summer period and in 9 and 40 % of participants during the winter period, respectively. In children, serum 25(OH)D below 30 and 50 nmol/l were found in 5 and 42 % of participants (samples collected March-May), respectively. Higher 25(OH)D concentrations were associated with the summer season, vacations in sunny locations (adults), and dietary intake of vitamin D and use of vitamin D supplements, while lower concentrations were associated with a higher BMI and an origin outside of Europe. Concentrations of 25(OH)D were lower using the immunoassay than with the LC-MS assay, but associations with dietary factors and seasonal variability were similar. In conclusion, vitamin D intake was lower than the AR, especially in children. The 25(OH)D concentrations were low in many participants, but few participants had a concentration below 30 nmol/l.


Subject(s)
Dietary Supplements , Nutritional Requirements , Osteomalacia/prevention & control , Rickets/prevention & control , Vitamin D Deficiency/prevention & control , Vitamin D/administration & dosage , Adolescent , Adult , Aged , Aged, 80 and over , Child , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Sweden , Vitamin D/blood , Young Adult
5.
Natl Med J India ; 32(1): 38-40, 2019.
Article in English | MEDLINE | ID: mdl-31823940

ABSTRACT

Aluminium utensils are ubiquitous in Indian households and other developing countries. Concerns have recently been raised on the pathological effects of aluminium on the human body, due to its leaching from utensils with long-term use, which has been associated with certain clinical conditions such as anaemia, dementia and osteo-malacia. While some studies suggest that cooking in utensils or aluminium foils is safe, others suggest that it may lead to toxic levels of aluminium in the body. However, studies have shown that leaching of aluminium from cooking utensils depends on many factors such as pH, temperature and cooking medium. In healthy controls, 0.01 %-1 % of orally ingested aluminium is absorbed from the gastrointestinal tract and is eliminated by the kidney. Although the metal has a tendency to accumulate in tissues and may result in their dysfunction, the literature suggests that the apprehension is more apt in patients with chronic renal insufficiency. This article offers solutions to mitigate the risk of aluminium toxicity.


Subject(s)
Aluminum/pharmacokinetics , Cooking and Eating Utensils/standards , Intestinal Absorption , Manufacturing Industry/standards , Renal Elimination , Aluminum/standards , Aluminum/toxicity , Anemia/chemically induced , Anemia/prevention & control , Cooking and Eating Utensils/legislation & jurisprudence , Dementia/chemically induced , Dementia/prevention & control , Hot Temperature/adverse effects , Humans , India , Manufacturing Industry/legislation & jurisprudence , Osteomalacia/chemically induced , Osteomalacia/prevention & control , Time Factors
6.
Endocr Rev ; 40(4): 1109-1151, 2019 08 01.
Article in English | MEDLINE | ID: mdl-30321335

ABSTRACT

The etiology of endemic rickets was discovered a century ago. Vitamin D is the precursor of 25-hydroxyvitamin D and other metabolites, including 1,25(OH)2D, the ligand for the vitamin D receptor (VDR). The effects of the vitamin D endocrine system on bone and its growth plate are primarily indirect and mediated by its effect on intestinal calcium transport and serum calcium and phosphate homeostasis. Rickets and osteomalacia can be prevented by daily supplements of 400 IU of vitamin D. Vitamin D deficiency (serum 25-hydroxyvitamin D <50 nmol/L) accelerates bone turnover, bone loss, and osteoporotic fractures. These risks can be reduced by 800 IU of vitamin D together with an appropriate calcium intake, given to institutionalized or vitamin D-deficient elderly subjects. VDR and vitamin D metabolic enzymes are widely expressed. Numerous genetic, molecular, cellular, and animal studies strongly suggest that vitamin D signaling has many extraskeletal effects. These include regulation of cell proliferation, immune and muscle function, skin differentiation, and reproduction, as well as vascular and metabolic properties. From observational studies in human subjects, poor vitamin D status is associated with nearly all diseases predicted by these extraskeletal actions. Results of randomized controlled trials and Mendelian randomization studies are supportive of vitamin D supplementation in reducing the incidence of some diseases, but, globally, conclusions are mixed. These findings point to a need for continued ongoing and future basic and clinical studies to better define whether vitamin D status can be optimized to improve many aspects of human health. Vitamin D deficiency enhances the risk of osteoporotic fractures and is associated with many diseases. We review what is established and what is plausible regarding the health effects of vitamin D.


Subject(s)
Bone and Bones/metabolism , Calcium/metabolism , Vitamin D/metabolism , Animals , Bone and Bones/physiology , Female , Humans , Male , Osteomalacia/drug therapy , Osteomalacia/prevention & control , Rickets/drug therapy , Rickets/prevention & control , Signal Transduction , Vitamin D/physiology , Vitamin D/therapeutic use , Vitamin D Deficiency/drug therapy , Vitamin D Deficiency/prevention & control
7.
Rev. méd. Hosp. José Carrasco Arteaga ; 10(2): 133-138, Jul 2018. Tablas, Gáficos
Article in Spanish | LILACS | ID: biblio-1000256

ABSTRACT

INTRODUCCIÓN: La Vitamina D es considerada una hormona, siendo químicamente liposoluble y se le relaciona con enfermedades inmunológicas, cardiometabólicas y cáncer. El objetivo es evaluar los niveles de 25 hidroxi vitamina D en los pacientes que acudieron al servicio de endocrinología. MÉTODOS: Se trata de un estudio retrospectivo, se tomaron 122 pacientes que acudieron al servicio de endocrinología del Instituto Ecuatoriano de Seguridad Social, durante el periodo durante el periodo de julio a septiembre del 2017. RESULTADOS: El promedio de vitamina D 23.99 ± 9.12 ng/ml, el 22 % presentaron vitamina D en rango normal (≥ 30 ng/ml) y el 78 % en insuficiencia/deficiencia (< 30 ng/ml). Los niveles de calcio y paratiroides no presentaron correlación con las disminuciones de vitamina D. CONCLUSIONES: Existe una importante disminución de la vitamina D en la población que acudió al servicio de Endocrinología durante el periodo estudiado, pese a la exposición solar directa que reciben los pobladores de la zona.


BACKGROUND: Vitamin D is considered a hormone, being chemically lipid soluble and is related to immunological, cardiometabolic and cancer diseases. This aim to evaluate the levels of 25 hydroxy vitamin D in the patients who attended the endocrinology service. METHODS: This was a retrospective study, taking 122 patients who attended the endocrinology service of the Ecuadorian Social Security Institute, during the period during the period from July to September 2017. RESULTS: The average of vitamin D was 23.99 ± 9.12 ng / ml, 22 % of vitamin D in normal range (≥ 30 ng / ml) and 78 % of insufficiency / deficiency (≥ 30 ng / ml). Calcium and parathyroid levels show no correlation with decreases in vitamin D. CONCLUSIONS: There is a significant decrease in the population in the population that went to the Endocrinology service during the period studied, to the direct solar incidence that the inhabitants of the area.


Subject(s)
Humans , Male , Female , Vitamin D/blood , Vitamin D Deficiency/etiology , Osteomalacia/prevention & control
8.
Arch Dis Child ; 103(9): 901-906, 2018 09.
Article in English | MEDLINE | ID: mdl-29661756

ABSTRACT

The consequences of vitamin D and dietary calcium deficiency have become a huge public health concern in the UK. The burden of disease from these deficiencies includes rickets, and hypocalcaemic seizures, dilated cardiomyopathy and mostly occult myopathy and osteomalacia. The increasing burden of the disease is intrinsically linked to ethnicity and the population demographic changes in the UK. Three facts have led to the resurfacing of the English disease: (1) the UK has no ultraviolet sunlight for at least 6 months of the year, (2) dark skin produces far less vitamin D than white skin per unit ultraviolet light exposure, and (3) non-European Union immigration over the last century. To date, the UK government demonstrates incomplete understanding of these three facts, and its failure to adjust its prevention programmes to changing demographics is endangering the health and life of UK residents with dark skin, of whom infants are the most vulnerable. Establishing accountability through the implementation of monitored antenatal and infantile supplementation programmes and mandatory food fortification is overdue.


Subject(s)
Government , Health Promotion/methods , Rickets/prevention & control , Dietary Supplements , Humans , Osteomalacia/epidemiology , Osteomalacia/prevention & control , Politics , Public Health/methods , Rickets/epidemiology , United Kingdom/epidemiology , Vitamin D/therapeutic use
9.
Toxicol Ind Health ; 33(11): 855-866, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28884628

ABSTRACT

Cadmium (Cd) and lead (Pb) are toxic elements that accumulate to the largest extent in bones. Rats were used to investigate whether tannic acid (TA; 0.5%, 1.0%, 1.5%. 2.0%, or 2.5%) would have a protective effect on the structure and properties of bones in the case of exposure to Cd and Pb (diet: 7 mg Cd/kg and 50 mg Pb/kg) for 6 weeks. The effects of administration of TA in Cd- and Pb-poisoned rats on bone characteristics and the morphology of articular and growth cartilages were determined. All the rats administered Cd and Pb had an enhanced Cd and Pb concentration in blood plasma and bone and reduced bone Ca content irrespective of the TA administration. Cd and Pb alone reduced the mechanical endurance and histomorphometric parameters of trabecular bone and the thickness of the growth plate and articular cartilage. Tannic acid improved cancellous bone parameters in the rat exposed to Cd and Pb. A diet rich in TA improved articular cartilage constituents in heavy metal-poisoned rats. These results suggest that alimentary TA supplementation can counteract in a dose-dependent manner some of the destructive changes evoked by Cd and Pb possibly by reducing the exposure.


Subject(s)
Bone and Bones/drug effects , Cadmium Poisoning/prevention & control , Cartilage, Articular/drug effects , Growth Plate/drug effects , Lead Poisoning/prevention & control , Protective Agents/therapeutic use , Tannins/therapeutic use , Animals , Biomechanical Phenomena/drug effects , Bone Density/drug effects , Bone Density Conservation Agents/administration & dosage , Bone Density Conservation Agents/therapeutic use , Bone and Bones/chemistry , Bone and Bones/pathology , Cadmium/blood , Cadmium/toxicity , Cadmium Poisoning/pathology , Cadmium Poisoning/physiopathology , Calcium/blood , Cancellous Bone/chemistry , Cancellous Bone/drug effects , Cancellous Bone/pathology , Cartilage, Articular/chemistry , Cartilage, Articular/pathology , Dose-Response Relationship, Drug , Growth Plate/chemistry , Growth Plate/pathology , Lead/blood , Lead/toxicity , Lead Poisoning/pathology , Lead Poisoning/physiopathology , Male , Osteomalacia/etiology , Osteomalacia/prevention & control , Osteoporosis/etiology , Osteoporosis/prevention & control , Protective Agents/administration & dosage , Random Allocation , Rats, Wistar , Tannins/administration & dosage , Toxicokinetics
10.
Endocr J ; 64(10): 1033-1039, 2017 Oct 28.
Article in English | MEDLINE | ID: mdl-28768937

ABSTRACT

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome often associated with fibroblast growth factor 23 (FGF23)-producing tumors such as phosphaturic mesenchymal tumor, mixed connective tissue variant (PMTMCT) affecting the bone and soft tissue. We experienced a patient with progressive bone and muscle pain due to FGF23-related TIO. Venous sampling had strongly suggested the anterior skull base as a source of FGF23, which led to the discovery of a small tumor in the ethmoid sinus extending intracranially. Radical surgical resection confirmed the histological diagnosis of PMTMCT with FGF23 immunopositivity and achieved durable tumor control with complete resolution of symptoms. We serially measured serum FGF23 level before, during and after surgery and analyzed the data to determine the half-life of FGF23. Serum FGF23 level sharply declined as early as 20 minutes after en bloc tumor resection and completely normalized after surgery. The half-life of FGF23 was calculated to be approximately 18.5 minutes using single phase exponential decay model as well as semilog transformation formula. Serial measurements of serum FGF23 level can potentially declare "complete" resection of a FGF23-producing tumor and total cure of TIO; in this regard, development of its intraoperative measurement would be helpful in the management of this endocrine tumor.


Subject(s)
Fibroblast Growth Factors/blood , Neoplasms, Complex and Mixed/surgery , Osteomalacia/prevention & control , Skull Base Neoplasms/surgery , Adult , Ethmoid Sinus , Female , Fibroblast Growth Factor-23 , Half-Life , Humans , Neoplasms, Complex and Mixed/blood , Neoplasms, Complex and Mixed/physiopathology , Osteomalacia/etiology , Skull Base Neoplasms/blood , Skull Base Neoplasms/physiopathology , Treatment Outcome
11.
Curr Osteoporos Rep ; 15(4): 293-302, 2017 08.
Article in English | MEDLINE | ID: mdl-28612338

ABSTRACT

PURPOSE OF REVIEW: Nutritional rickets and osteomalacia are common in dark-skinned and migrant populations. Their global incidence is rising due to changing population demographics, failing prevention policies and missing implementation strategies. The calcium deprivation spectrum has hypocalcaemic (seizures, tetany and dilated cardiomyopathy) and late hypophosphataemic (rickets, osteomalacia and muscle weakness) complications. This article reviews sustainable prevention strategies and identifies areas for future research. RECENT FINDINGS: The global rickets consensus recognises the equal contribution of vitamin D and dietary calcium in the causation of calcium deprivation and provides a three stage categorisation for sufficiency, insufficiency and deficiency. For rickets prevention, 400 IU daily is recommended for all infants from birth and 600 IU in pregnancy, alongside monitoring in antenatal and child health surveillance programmes. High-risk populations require lifelong supplementation and food fortification with vitamin D or calcium. Future research should identify the true prevalence of rickets and osteomalacia, their role in bone fragility and infant mortality, and best screening and public health prevention tools.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Calcium, Dietary/therapeutic use , Osteomalacia/prevention & control , Rickets/prevention & control , Vitamin D/therapeutic use , Health Policy , Humans , Public Health
13.
Arch Dis Child ; 101(2): 185-9, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26203122

ABSTRACT

The classical clinical consequence of vitamin D deficiency is osteomalacia, presenting as rickets in children. This remains a common problem in parts of the Middle East and the Indian subcontinent, and occurs when serum 25-hydroxyvitamin D levels are <25 nmol/L. Osteomalacia remains the only problem that is unequivocally a consequence of vitamin D deficiency. Low levels of 25-hydroxyvitamin D are observed in a wide range of conditions, but consistent trial evidence of amelioration of these conditions with vitamin D is lacking. Monotherapy with vitamin D has not been found to be effective in meta-analyses of trials assessing its effects on bone density, fractures or falls. At present, supplements should be advised for individuals at risk of having serum 25-hydroxyvitamin D levels in the 25-40 nmol/L range, or below, with a view to prevention of osteomalacia.


Subject(s)
Vitamin D Deficiency/complications , Accidental Falls/prevention & control , Dietary Supplements , Humans , Osteomalacia/blood , Osteomalacia/prevention & control , Osteoporotic Fractures/prevention & control , Randomized Controlled Trials as Topic/methods , Vitamin D/analogs & derivatives , Vitamin D/blood , Vitamin D/therapeutic use , Vitamin D Deficiency/blood
14.
Best Pract Res Clin Endocrinol Metab ; 29(3): 385-98, 2015 Jun.
Article in English | MEDLINE | ID: mdl-26051298

ABSTRACT

Calcium and phosphorus represent building material for bones. The supplier of these bone minerals is the hormone calcitriol, which originates from vitamin D, itself made by sunshine in human skin. Requirement for bone minerals is highest during phases of rapid growth, and no one grows faster than the foetus and the infant, making them particularly vulnerable. Deprivation of calcium, whether through low calcium intake or low vitamin D, leads to serious health consequences throughout life, such as hypocalcaemic seizures, dilated cardiomyopathy, skeletal myopathy, congenital and infantile rickets, and osteomalacia. These 5 conditions are often summarised as 'symptomatic vitamin D deficiency', are fully reversible but also fully preventable. However, the increasing prevalence of rickets and osteomalacia, and the deaths from hypocalcaemic cardiomyopathy, demand action from global health care providers. Clarification of medical and parental responsibilities is a prerequisite to deliver successful prevention programmes. The foetus and infant have the human right to be protected against harm, and vitamin D supplementation has the same public health priority as vaccinations.


Subject(s)
Calcium, Dietary/therapeutic use , Calcium/deficiency , Cardiomyopathy, Dilated/prevention & control , Osteomalacia/prevention & control , Pregnancy Complications/prevention & control , Rickets/prevention & control , Seizures/prevention & control , Vitamin D Deficiency/prevention & control , Vitamins/therapeutic use , Calcitriol/therapeutic use , Cardiomyopathy, Dilated/etiology , Cholecalciferol/therapeutic use , Ergocalciferols/therapeutic use , Female , Fetal Diseases/etiology , Fetal Diseases/prevention & control , Humans , Infant , Infant, Newborn , Osteomalacia/etiology , Pregnancy , Rickets/congenital , Rickets/etiology , Seizures/etiology , Vitamin D Deficiency/complications
15.
BMJ Case Rep ; 20142014 May 14.
Article in English | MEDLINE | ID: mdl-24827649

ABSTRACT

The case of a recurrent phosphaturic mesenchymal tumour of the maxillary sinus 10 years after the first surgical excision is reported. The neoplasm first presented with paraneoplastic osteomalacia causing a pathological femur fracture. A right maxillary sinus tumour was identified and treated thereafter. The patient had no local symptoms and serum electrolytes returned to normal after surgical removal of the tumour. However, 10 years later, the patient's urine Ca and P levels increased and an octreoscan detected a new tumour in the right maxillary sinus. Early diagnosis prevented the effects of the paraneoplastic activity of the neoplasm. This case emphasises the importance of specific, close follow-up, because the neoplasm rarely produces local signs indicating its position. To our knowledge, this is the first reported case of a late relapse presenting without relevant symptoms (local pain or swelling or pathological fractures).


Subject(s)
Calcium/metabolism , Hypophosphatemia/diagnosis , Maxillary Sinus Neoplasms/diagnosis , Neoplasm Recurrence, Local/diagnosis , Osteomalacia/metabolism , Phosphates/metabolism , Phosphorus/metabolism , Bone Density , Early Diagnosis , Female , Femoral Fractures/etiology , Femoral Fractures/metabolism , Fractures, Spontaneous/etiology , Fractures, Spontaneous/metabolism , Humans , Hypophosphatemia/etiology , Hypophosphatemia/metabolism , Maxillary Sinus/pathology , Maxillary Sinus Neoplasms/complications , Maxillary Sinus Neoplasms/metabolism , Neoplasm Recurrence, Local/metabolism , Osteomalacia/etiology , Osteomalacia/prevention & control
17.
J Clin Endocrinol Metab ; 98(11): E1702-9, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24064695

ABSTRACT

CONTEXT: Bone health is influenced by the intake of both calcium and vitamin D. OBJECTIVE: Our objective was to evaluate the influence of calcium and vitamin D supplementation on PTH and bone turnover. SETTING, PATIENTS, AND DESIGN: At an ambulatory research center, 159 postmenopausal healthy white women participated in this double-blind, placebo-controlled parallel, longitudinal factorial study that was 6 months in duration. INTERVENTIONS: Subjects were randomly allocated to 4 groups: 1) double placebo, 2) calcium (1200 mg daily) plus placebo, 3) vitamin D3 (100 µg) plus placebo, and 4) vitamin D3 and calcium. Serum and urine were collected fasting and 2 hours after a calcium load at baseline and at 3 and 6 months. MAIN OUTCOME MEASURES: Serum PTH, cross-linked C-telopeptide (CTX), and procollagen type I N-terminal propeptide (P1NP) were measured. RESULTS: Before study medication, a calcium load resulted in a decline in PTH and CTX and an increase in urinary calcium excretion. Serum CTX and P1NP declined over time with calcium supplementation but did not change with increased vitamin D intake. There was a decline in PTH in the vitamin D groups in the fasting state compared with placebo. Suppression of PTH was greater after a calcium load in the vitamin D groups. A calcium load decreased PTH and CTX and raised urinary calcium. CONCLUSIONS: Fasting PTH declines with vitamin D supplementation. PTH declines after calcium intake. Supplementation of the diet with 1200 mg calcium/d reduces bone turnover markers, whereas supplementation with up to100 µg vitamin D3/d does not.


Subject(s)
Bone Remodeling/drug effects , Bone and Bones/drug effects , Calcium, Dietary/administration & dosage , Cholecalciferol/administration & dosage , Osteoporosis/prevention & control , Postmenopause/drug effects , Aged , Bone and Bones/metabolism , Calcium/urine , Calcium, Dietary/adverse effects , Cholecalciferol/adverse effects , Collagen Type I/blood , Dietary Supplements , Female , Fractures, Bone/prevention & control , Humans , Longitudinal Studies , Middle Aged , Osteomalacia/prevention & control , Parathyroid Hormone/blood , Peptide Fragments/blood , Peptides/blood , Placebos , Procollagen/blood , Vitamins/administration & dosage , Vitamins/adverse effects
18.
Endocrinol Metab Clin North Am ; 41(3): 557-69, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22877429

ABSTRACT

Vitamin D is important for the normal development and maintenance of bone. The elucidation of the vitamin D activation pathway and the cloning of the vitamin D receptor have advanced our understanding of the actions of vitamin D on bone. The preponderance of evidence indicates that 1,25(OH)2D3 enhances bone mineralization through its effects to promote calcium and phosphate absorption. Although 1,25(OH)2D3 stimulates bone resorption in vitro, treatment in vivo can prevent bone loss and fracture through several potential mechanisms. The development of vitamin D analogues has provided new therapeutic options for increasing bone mineral density and reducing fractures.


Subject(s)
Bone Development , Bone Resorption/prevention & control , Bone and Bones/metabolism , Calcification, Physiologic , Vitamin D/therapeutic use , Animals , Calcitriol/metabolism , Dietary Supplements , Female , Fractures, Bone/prevention & control , Humans , Male , Osteomalacia/diet therapy , Osteomalacia/metabolism , Osteomalacia/prevention & control , Osteoporosis/diet therapy , Osteoporosis/etiology , Osteoporosis/prevention & control , Rickets/diet therapy , Rickets/metabolism , Rickets/prevention & control , Vitamin D/metabolism
19.
PLoS One ; 7(5): e37569, 2012.
Article in English | MEDLINE | ID: mdl-22629419

ABSTRACT

Fibroblast growth factor-2 (FGF2) has been demonstrated to be a promising osteogenic factor for treating osteoporosis. Our earlier study shows that transplantation of mouse Sca-1(+) hematopoietic stem/progenitor cells that are engineered to express a modified FGF2 leads to considerable endosteal/trabecular bone formation, but it also induces adverse effects like hypocalemia and osteomalacia. Here we report that the use of an erythroid specific promoter, ß-globin, leads to a 5-fold decrease in the ratio of serum FGF2 to the FGF2 expression in the marrow cavity when compared to the use of a ubiquitous promoter spleen focus-forming virus (SFFV). The confined FGF2 expression promotes considerable trabeculae bone formation in endosteum and does not yield anemia and osteomalacia. The avoidance of anemia in the mice that received Sca1(+) cells transduced with FGF2 driven by the ß-globin promoter is likely due to attenuation of high-level serum FGF2-mediated stem cell mobilization observed in the SFFV-FGF2 animals. The prevention of osteomalacia is associated with substantially reduced serum Fgf23/hypophosphatemia, and less pronounced secondary hyperparathyroidism. Our improved stem cell gene therapy strategy represents one step closer to FGF2-based clinical therapy for systemic skeletal augmentation.


Subject(s)
Bone Marrow/metabolism , Fibroblast Growth Factor 2/genetics , Hematopoietic Stem Cell Transplantation/methods , Osteogenesis , Osteomalacia/prevention & control , beta-Globins/genetics , Animals , Fibroblast Growth Factor 2/metabolism , Fibroblast Growth Factor-23 , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cells/metabolism , Mice , Osteomalacia/etiology , Promoter Regions, Genetic
20.
Curr Osteoporos Rep ; 10(2): 151-9, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22544628

ABSTRACT

All cells comprising the skeleton-chondrocytes, osteoblasts, and osteoclasts-contain both the vitamin D receptor and the enzyme CYP27B1 required for producing the active metabolite of vitamin D, 1,25 dihydroxyvitamin D. Direct effects of 25 hydroxyvitamin D and 1,25 dihydroxyvitamin D on these bone cells have been demonstrated. However, the major skeletal manifestations of vitamin D deficiency or mutations in the vitamin D receptor and CYP27B1, namely rickets and osteomalacia, can be corrected by increasing the intestinal absorption of calcium and phosphate, indicating the importance of indirect effects. On the other hand, these dietary manipulations do not reverse defects in osteoblast or osteoclast function that lead to osteopenic bone. This review discusses the relative importance of the direct versus indirect actions of vitamin D on bone, and provides guidelines for the clinical use of vitamin D to prevent/treat bone loss and fractures.


Subject(s)
Bone and Bones/physiology , Vitamin D/physiology , Animals , Dietary Supplements , Humans , Models, Animal , Osteomalacia/prevention & control , Rickets/prevention & control , Vitamin D/administration & dosage , Vitamin D/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...